ArticleApoptosis : an international journal on programmed cell death2026
Targeted delivery of RGD-JEG-3-EVs for placental vascular regeneration in preeclampsia: from molecular mechanism toward therapy.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Preeclampsia (PE) is a hypertensive disorder of pregnancy associated with placental dysfunction and vascular maladaptation. Defective remodeling of maternal spiral arteries leads to placental ischemia, a key driver of the maternal systemic syndrome. Extracellular vesicles (EVs) from highly invasive choriocarcinoma trophoblasts, which exhibit pro-angiogenic properties, represent a potential therapeutic resource. However, their utility for targeted therapy in PE remains unexplored. We engineered EVs derived from RGD-JEG-3-EVs on activated vasculature. The therapeutic potential and safety were evaluated in the L-NAME-induced rat model of gestational hypertension and endothelial dysfunction. A combination of in vivo imaging, functional assays in HUVECs, proteomic analysis, and molecular interventions was used to assess efficacy and mechanism. RGD-JEG-3-EVs exhibited preferential placental accumulation, alleviated maternal hypertension and proteinuria, improved fetal growth, and enhanced placental vascular density this model. Short-term tumorigenicity and toxicity assessments revealed no detectable adverse effects under experimental conditions. Proteomic profiling identified FASCIN as a key protein enriched in JEG-3-EVs. Functional studies indicated that FASCIN contributed to EV-mediated pro-angiogenic effects in a Wnt/β-catenin-dependent manner. Suppression of FASCIN attenuated the therapeutic benefits in vivo. This study provides proof-of-concept for using engineered RGD-JEG-3-EVs as a targeted strategy to deliver pro-angiogenic signals (FASCIN-Wnt/β-catenin signal) and improve placental vascular function in a rat model of gestational hypertension, supporting further investigation of this nanotherapeutic strategy.
Indexed as
Identifiers
41866647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.